Drug Profile


Alternative Names: CDA; Dacart; LAPDAP + artesunate

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Medicines for Malaria Venture; Special Programme for Research and Training in Tropical Diseases
  • Class Antimalarials; Artemisinins; Biguanides; Sesquiterpenes; Sulfones
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 08 Feb 2008 Chlorproguanil/dapsone/artesunate is still in phase III trials for uncomplicated malaria in sub-Saharan Africa
  • 26 Jul 2006 GlaxoSmithKline and Medicines for Malaria Venture have initiated two phase III trials for malaria in sub-Saharan Africa
  • 30 Nov 2005 Phase-III clinical trials in Malaria treatment in Africa (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top